ABSTRACT Improving quality and delivery of care for people with Alzheimer disease and related dementias (ADRD) requires a comprehensive research agenda that encompasses the entire care continuum. Logistical and ethical challenges of informed consent for research participation of persons with ADRD include determination of capacity to consent, surrogate consent when capacity to consent is compromised, timely identification of the legally authorized representative (LAR) providing surrogate consent, and balancing residual autonomy with surrogate consent. Short stays; limited access to patients, caregivers, and LARs; and fluctuating influences of acute illness on capacity determination compound these challenges in the acute care setting. To address these challenges, we worked with the University of Wisconsin Health Sciences Institutional Review Board to develop a procedural framework for obtaining informed consent from hospitalized individuals with ADRD and their caregivers to participate in a minimal risk care intervention. The framework is specially designed for minimal risk situations in which rapid enrollment is a necessity and uses rapid identification of surrogates to consent for patients who lack legal capacity to make medical decisions, indicated by an activated healthcare power of attorney, and individualized formal assent procedures for patients who lack capacity to consent. These methods were proven effective in facilitating hospital-based recruitment in an ongoing randomized controlled trial and provide a basis for increasing access to acute care clinical research for persons with ADRD. Bolstering research participation through more easily used consent procedures during acute illness is critical to fostering improvements in the delivery of high-quality care to persons with ADRD.
T he relentlessly rising prevalence of Alzheimer disease and related dementias (ADRD) reverberates through every facet of society. This is reflected in the continually rising costs for comprehensive ADRD care, which will reach $277 billion in the United States in 2018 and is estimated to reach more than $1 trillion by 2050. 1 Despite the scale of the growing epidemic, disease-modifying therapies have remained elusive, and the current fragmented healthcare system is ill equipped to manage the unique challenges of longitudinal ADRD care. 2 Improving the care processes of ADRD requires a comprehensive research agenda that encompasses the entire care continuum, including the acute care setting, but there are logistical and ethical challenges to informed consent for research participation of hospitalized persons with ADRD that are significant barriers to advancing this inclusive research agenda. [3] [4] [5] [6] Hospitalizations are common for persons with ADRD and are associated with greater risk of iatrogenic complications, protracted morbidity, and accelerated cognitive and functional decline. 7, 8 Hospitalizations are therefore an important area for investigation and intervention, although research enrollment opportunities are constrained. Overall lengths of stay can be brief, and stays are frequently used as respite for caregivers. 9 In addition to heightened time constraints, additional challenges of hospital-based consent include limited access to patients with ADRD, caregivers, and legally authorized representatives (LARs); fluctuating influences of acute illness on cognition; and the need to minimize interruptions to ongoing medical care. 4 There are four primary challenges to informed consent for persons with ADRD that are compounded in the acute care setting.
Determination of capacity to consent
Informed consent is a principal tenet and legal requirement of ethical research involving human subjects. 10 Informed consent is strongly anchored by individual autonomy, or deliberated self-rule, which becomes compromised in ADRD due to the neurodegenerative process that results in cognitive function loss. 11, 12 However, the presence of ADRD does not automatically preclude an individual from providing voluntary informed consent. Capacity to consent is situational and domain specific, necessitating individualized assessment. 13, 14 Judgements regarding capacity should also take into consideration the risk-benefit ratio of the respective decisions to be made, favoring higher thresholds for capacity in higher-risk situations. 13 
Surrogate consent when capacity to consent is compromised
Federal regulations, referred to as the Common Rule, require surrogate consent from a LAR when an individual lacks capacity to provide consent. 15 Surrogate consent for research follows the principal dictates of surrogate decision-making for health care, which relies on substituted judgment that is ideally based on previously expressed preferences or values that best approximate the individual's autonomy. 16 If there are no known or previously expressed preferences, the standard of best interest is relied upon for surrogate consent. 16 Advance research directives can provide prospective consent or facilitate substituted judgment, although they are uncommon. 17 Federal regulations offer limited procedural specifics for surrogate consent, resulting in wide variation between institutions and institutional review boards (IRBs). 18 IRBs are instrumental in defining the roles and responsibilities of individuals providing surrogate consent based on stratification of the potential risks and benefits of research participation. Surrogate consent is generally viewed as acceptable and appropriate for minimal-risk research, regardless of personal benefit. 19, 20 Alternatively, research involving greater than minimal risk requires the potential for personal benefit as a prerequisite for surrogate consent. The definition of personal benefit has tended to be broadly defined as inclusive of indirect or future theoretical benefit through the general advancement of knowledge through research. The principle of common good ethics has been used as a formal framework to broaden the inclusivity of personal benefit from research to include communal benefit. 21 This approach acknowledges both the individual altruism that frequently motivates participation, as well as the broader societal benefits of research.
Identification of LAR providing surrogate consent
Federal regulations delegate surrogate identification to the state level, although few states provide legal definitions of who is authorized to provide surrogate consent for research. 10, 15, 22 Consequently, there is significant variability across institutions and IRBs, although in general, the LAR for surrogate consent for research follows the hierarchy of the LAR for medical decision-making, with precedence given to court-appointed guardianship and healthcare power of attorney (HCPOA), and then typically follows next-of-kin delegation. 18 Some research suggests that people with ADRD who are identified as incapable of consenting to a medication trial are capable of appointing a research proxy, 13 but in some contexts, such as minimal-risk studies in which the participant is likely to incur direct benefits through improved clinical care, the burden of identifying a proxy while the person is acutely ill may not outweigh the risks of delegated decision-making capacity.
Balancing of residual autonomy with surrogate consent
The progression of ADRD lies on a continuum, and the necessary dichotomization of capacity determination creates an ethical challenge of appropriately balancing residual autonomy with the necessity of surrogate consent when capacity is compromised. "Periods of acute illness and hospitalization, during which individuals with ADRD are at risk of developing delirium and experiencing stress related to the unfamiliar environment and caregivers, can hasten the progression of ADRD." Unfortunately, the legal and regulatory dictates underpinning the consent process for persons who lack the capacity to provide their own consent has led to a predominant focus on institutional protection, often at the expense and frequent exclusion of the individual. 23 This exclusion has the potential to violate the ethical principles of autonomy, justice, and respect. 22 This form of moral exclusion of the individual creates an inherent tension with the ethical and regulatory necessity of surrogate consent for vulnerable persons with ADRD and the safeguarding against potential harm, coercion, exploitation, or undue influence. This is particularly important for an incurable disease with limited treatment options such as ADRD given the heightened risk for therapeutic misconception. 24 The tension between moral exclusion and safeguarding the well-being of this vulnerable population has led to formal integration of assent for research participation into the formal consent procedure by individuals who lack the capacity to consent. The right of assent was first laid out in the Declaration of Helsinki in 1964 and has been expanded to include any individual who is deemed "incapable of giving informed consent." 25 Assent allows flexible but formal permission for enrollment while respecting the right of refusal at any time. 3, 5, 6 In addition, participatory consent models for persons with ADRD have been developed that reject the standard informed consent model that prioritizes autonomy and focuses on relational aspects of ADRD care involving family and caregivers while maximizing individual engagement through assent. 3, 11, 23, 26 The challenges of informed consent of hospitalized persons with ADRD risks the indiscriminate exclusion of this subgroup or selection bias toward community or nursing home recruitment. 4, 5, 26, 27 Furthermore, because some research may constitute minimal risk for participants, with greater likelihood of direct and indirect benefits, identifying procedures that maximize inclusion in acute care settings is critical. To our knowledge, there are no standardized protocols for obtaining informed consent in this population for minimal-risk situations in acute care environments. We therefore developed a procedural framework to facilitate informed consent of hospitalized patients inclusive of all stages of ADRD. Our framework was developed within the context of a randomized controlled trial of a hospital-based transitional care intervention for persons with ADRD and their caregivers. The minimalrisk study randomized hospitalized patients with ADRD to enrollment in the Coordinated-Transitional Care Program (C-TraC) or usual care. 28 C-TraC is a low-cost, telephone-based transitional care program designed to improve posthospitalization care coordination and outcomes for patients discharged to the community. Caregivers are crucial to the C-TraC intervention and are enrolled separately from patients. We describe the process for development of our procedural framework and illustrate its application in the C-TraC trial.
METHODS
We used a 3-step process to develop the procedural framework for informed consent of hospitalized patients with ADRD: review of existing approaches and established legal and ethical standards; collaboration with the institutional IRB to discuss legal requirements, acute care-specific challenges, and appropriate modifications for the specific risk-benefit ratio (very low risk intervention); and scenariobased process mapping to inform development of an informed consent tool and the overarching framework. Because we were unable to locate any evidence of existing approaches or standards for facilitating real-time acute care-based consent of persons with ADRD, we identified existing approaches for adaptation to the acute care setting. 26 In collaboration with the IRB, we simultaneously reviewed legal decision-making capacity evaluation requirements according to application of the Common Rule. Although capacity is often broadly considered risk specific and situational, federal regulations have not provided adequate guidance for situations in which legal incapacity exists and is inconsistent with research-specific decisional capacity. 29, 30 Existing requirements evaluate decisionmaking capacity using legal designations of incapacity, such as those designated through formal incapacity assessments. In the clinical context of the present intervention study, capacity was mandatorily re-evaluated as a routine component of patient care. The situational context of clinical decision-making was deemed equivalent to the context of a care-based research intervention with almost no patient contact and minimal associated risk. Thus, in the developed procedural framework the patient's ability to provide consent is initially evaluated by reviewing their legal decision-making capacity status. By virtue of existing legal requirements, any patients lacking capacity to make medical decisions for themselves are unable to provide formal informed consent and must have a LAR provide such consent. 15 For patients lacking capacity, formal assent was obtained based on previously published standards. 3, 6, 26 The overarching procedural framework incorporated the capacity assessment and explicitly identified the multiple permutations for obtaining informed consent and assent from hospitalized patients with ADRD or their LAR, as well as the informal caregiver who was often, but not always, the LAR. We used process mapping to critique and streamline the process of navigating consent requirements and decision-making for the study team while also critiquing the number and complexity of assessments, forms, and contact points for patients and caregivers.
RESULTS
The process map includes 8 potential scenarios encountered during the consent process broadly categorized around the patient's capacity to consent and the physical presence of the LAR and caregiver (Figure 1 ). In this low-risk trial, capacity to consent is determined according to a patient's legal capacity to consent to medical treatment as indicated by an activated HCPOA. Patients with an activated HCPOA are deemed incapacitated to consent to research, and surrogate consent is obtained from the LAR designated in the HCPOA.
For patients who do not have capacity to consent, informed consent is obtained from the LAR in person through written consent or over the telephone through verbal consent. To the maximum extent possible, the patient participates in the consent discussion and is given the opportunity to ask questions. Along with surrogate consent, formal assent from the patient is obtained and is customized to the individual's cognitive ability and means of expressing preferences, including behavioral and emotional cues as identified in the literature. 6 For example, in less-verbal patients, passive cooperation with activities can suggest implied permission, whereas agitation or restlessness during an interaction can indicate dissent. If feasible, verbal affirmative assent is obtained after a simplified description of the research study and the associated risks, benefits, and alternatives to participation, although there are individuals who cannot provide active assent, such as those with aphasia or who lack comprehension of even simplified descriptions of the study. In these situations, passive assent is obtained through behavioral cues or lack of overt dissent based on aberrations from baseline, ideally with input from family and caregivers. For example, a patient who regularly engages with hospital staff but consistently turns away from the research specialist would be suggestive of expressive dissent. Alternatively, if this response is consistent with baseline behaviors and there is no other evidence of distress or opposition, then lack of overt dissent could be inferred as passive assent. If the patient dissents, the research team will meet separately with the LAR and caregiver and work together to help address underlying concerns and alleviate any contributing distress before reengaging with the patient one additional time. For example, the patient may misconstrue the research specialist as a threat but be more receptive with reassurance from a family member. Persistent dissent is respected, regardless of the underlying reasoning, and the patient is not enrolled. Passive assent is continually monitored throughout the study, with active reassessment as needed. If the patient is enrolled after surrogate consent and assent are obtained, written or verbal consent is obtained separately from the caregiver.
Patients who have capacity to consent are provided with the written consent form and given appropriate time for discussion and family and caregiver involvement at the discretion of the patient. Patients are monitored for evidence of undue miscomprehension throughout the consent process, including frequent repetition, sustained inattention, frequent misunderstandings, and vague or nonsensical statements. Patients are ineligible for enrollment if there are any concerns regarding retained capacity.
DISCUSSION
Informed consent is an important mechanism for providing ethical research inclusivity while safeguarding against potential harm, coercion, exploitation, or undue influence, but the additional challenges of the informed consent process for hospitalized patients with ADRD risk marginalizing this important population from meaningful contributions and resultant benefits of research. Building on established ethical, legal, and regulatory principles, as well as consent protocols for non-acute care settings, we developed a procedural framework to facilitate informed consent of hospitalized patients and caregivers inclusive of all stages of ADRD to participate in a minimal-risk care intervention. 26 The procedural framework addresses the 4 primary challenges of informed consent for persons with ADRD while specifically focusing on the acute care setting, where rapid enrollment is necessary. The first challenge is determination of capacity to provide consent. We used a patient's legal capacity to consent to inpatient medical treatment, as indicated by HCPOA activation, as a proxy to consent for research. Although there are tools to assess for comprehensive research-specific capacity, they are impractical to administer in the busy, time-constrained setting of an acute care hospital for studies that pragmatically require rapid hospital-based enrollment and are of minimal risk. 31 The use of an activated HCPOA as a proxy for capacity to consent for research specifically capitalizes on the hospital setting, where inpatient providers continually assess capacity as a part of usual care for timely medical decision-making. This is of particular importance given the high incidence of delirium and fluctuating cognition in hospitalized patients with ADRD. The capacity assessment for medical decisionmaking is a well-established standard that is based on independent assessments by two physicians. This integration into the usual care of hospitalized patients streamlines the capacity assessment with minimal interruption to ongoing medical care.
The procedural framework also addresses the challenges of surrogate consent for incapacitated patients and LAR identification by using the HCPOA agent as the LAR providing surrogate consent. Surrogate consent is ideally based on substituted judgment or, barring known preferences, on the standard of best interest. Using the HCPOA agent as the surrogate best approximates these standards because it is the legal representative that the patient has designated to make decisions on his or her behalf and selected before he or she became incapacitated. Although the standards of substituted judgment and best interest are difficult to gauge, there is broad public support for surrogate-based research enrollment, with considerable latitude afforded to the surrogate. 32, 33 In addition, the allowance of verbal consent integrated into the process map allows flexibility and efficiency when obtaining surrogate consent.
The final challenge that the procedural framework addresses is the balancing of an individual's residual autonomy with the need for surrogate consent. Maximally involving the patient, regardless of ADRD stage, in all aspects of the consent process, including informally through group discussions and formally through informed consent or assent, addresses this challenge. Assent was individualized based on cognitive ability, baseline behavioral manifestations of ADRD, and personal means of expressing preferences. 3, 6 In addition, passive assent was continually monitored throughout the study, with active reassessment as needed.
Although not used in this study, customized communication aids, such as Talking Mats, visual cue cards, and speech devices, may help facilitate the information sharing and assent process. 34, 35 There are limitations to the procedural framework. It was derived for hospital-based recruitment for a clinical trial with minimal associated risk. Generalizability to ambulatory settings or to studies with greater than minimal risk is uncertain and would merit further investigation, but the framework allows a degree of adaptability. For example, longer-time frame longitudinal studies may institute periodic capacity reevaluations, formal ongoing assent appraisal, and identification and early involvement of a LAR for persons with capacity at enrollment given the progressive nature of ADRD. One of the core development features of this framework was the close collaboration with the IRB to gauge and mitigate risk and to ensure that appropriate safeguards were in place for participant wellbeing, although this was inherently a low-risk study.
Research studies with greater risk may require additional procedural safeguards, such as independent monitors and processes for continuous assent appraisal. In addition, the changing interactions involving risk, surrogate consent, and novel research methodologies require careful consideration in research involving persons with ADRD. 21 In summary, we developed a procedural framework for obtaining hospital-based informed consent from patients with ADRD and their caregivers to participate in a minimal-risk care intervention. The framework was a multidisciplinary collaboration with early and ongoing input from the IRB. Persons with ADRD, especially in the late stages, have historically been marginalized from research and the consent process, with potentially serious implications given the rising disease prevalence with an aging demographic, the paucity of effective treatment options, and the growing strain on an ill-equipped healthcare system. Bolstering research participation through more readily engaged consent procedures during acute illness is critical to fostering improvements in the delivery of high-quality care to persons with ADRD. This procedural framework helps address the challenge of an inclusive and participatory research agenda for persons with ADRD, which is a direct reflection of how we value our fellow members of the human race who live with dementia.
